Considering that HCC patients with high G6PD levels have better sensitivity to sorafenib and the role of G6PD in the immune microenvironment, the combination of immune checkpoint inhibitors (CPIs) can be considered, which may yield better efficacy. The gene discussed is G6PD; the disease is hepatocellular carcinoma.